157 related articles for article (PubMed ID: 37580574)
1. Successful treatment by CAR T-cells in multi-refractory mantle cell lymphoma with central nervous system involvement.
Caillet A; Houillier C; Sourdeau E; Gazzano M; Uzunov M; Friser V; Ribeiro M; Nicelli L; Azar N; Baron M; Phina-Ziebin X; Choquet S; Roos-Weil D
Ann Hematol; 2023 Nov; 102(11):3295-3297. PubMed ID: 37580574
[No Abstract] [Full Text] [Related]
2. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
Ryan CE; Zon RL; Redd R; Fisher DC; Shouval R; Kumar A; Crombie JL; Sadrzadeh H; Kim AI; Nayak L; Chukwueke UN; Jacobson CA; Frigault MJ; Palomba ML; Armand P; Epstein-Peterson Z; Merryman RW
Br J Haematol; 2023 Dec; 203(5):774-780. PubMed ID: 37584155
[TBL] [Abstract][Full Text] [Related]
3. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
[TBL] [Abstract][Full Text] [Related]
4. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
6. Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma.
Zhang W; Huang C; Liu R; Zhang H; Li W; Yin S; Wang L; Liu W; Liu L
Front Immunol; 2022; 13():983934. PubMed ID: 36275715
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Lionel AC; Gurumurthi A; Fetooh A; Eldaya R; Ahmed S; Iyer SP; Nastoupil LJ; Westin J; Nair R; Fayad L; Malpica L; Tummala S; Flowers C; Neelapu SS; Wang ML; Jain P
Leuk Lymphoma; 2024 May; 65(5):669-673. PubMed ID: 38248629
[No Abstract] [Full Text] [Related]
8. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
9. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
[TBL] [Abstract][Full Text] [Related]
10. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
Mulazzani M; Fräßle SP; von Mücke-Heim I; Langer S; Zhou X; Ishikawa-Ankerhold H; Leube J; Zhang W; Dötsch S; Svec M; Rudelius M; Dreyling M; von Bergwelt-Baildon M; Straube A; Buchholz VR; Busch DH; von Baumgarten L
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24275-24284. PubMed ID: 31712432
[TBL] [Abstract][Full Text] [Related]
11. Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
Kline K; Luetkens T; Koka R; Kallen ME; Chen W; Ahmad H; Omili D; Iraguha T; Gebru E; Fan X; Miller A; Dishanthan N; Baker JM; Dietze KA; Hankey KG; Yared JA; Hardy NM; Rapoport AP; Dahiya S; Atanackovic D
Cancer Immunol Immunother; 2024 Feb; 73(3):45. PubMed ID: 38349430
[TBL] [Abstract][Full Text] [Related]
12. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
Zhang H; Yan Z; Wang Y; Qi Y; Hu Y; Li P; Cao J; Zhang M; Xiao X; Shi M; Xia J; Ma S; Qiao J; Li H; Pan B; Qi K; Cheng H; Sun H; Zhu F; Sang W; Li D; Li Z; Zheng J; Zhao M; Liang A; Huang H; Xu K
Front Immunol; 2022; 13():965224. PubMed ID: 36059496
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
17. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.
Cheah CY; George A; Giné E; Chiappella A; Kluin-Nelemans HC; Jurczak W; Krawczyk K; Mocikova H; Klener P; Salek D; Walewski J; Szymczyk M; Smolej L; Auer RL; Ritchie DS; Arcaini L; Williams ME; Dreyling M; Seymour JF;
Ann Oncol; 2013 Aug; 24(8):2119-23. PubMed ID: 23616279
[TBL] [Abstract][Full Text] [Related]
18. Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Karschnia P; Rejeski K; Winkelmann M; Schöberl F; Bücklein VL; Blumenberg V; Schmidt C; Blobner J; von Bergwelt-Baildon M; Tonn JC; Kunz WG; Subklewe M; von Baumgarten L
Neurology; 2022 May; 98(21):884-889. PubMed ID: 35351785
[TBL] [Abstract][Full Text] [Related]
19. CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma.
Su L; Wu L; Lobb RR; Rennert PD; Ambrose C
Oncoimmunology; 2022; 11(1):2111904. PubMed ID: 35990518
[TBL] [Abstract][Full Text] [Related]
20. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
Jiang VC; Hao D; Jain P; Li Y; Cai Q; Yao Y; Nie L; Liu Y; Jin J; Wang W; Lee HH; Che Y; Dai E; Han G; Wang R; Rai K; Futreal A; Flowers C; Wang L; Wang M
Mol Cancer; 2022 Sep; 21(1):185. PubMed ID: 36163179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]